May 22, 2026 09:30AM
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 15, 2026 06:31PM
Apr 13, 2026 07:00AM
Apr 1, 2026 08:01AM
Apr 1, 2026 08:00AM Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo
Mar 9, 2026 02:30AM
Feb 19, 2026 02:30AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM
Jan 13, 2026 07:00AM
Jan 13, 2026 07:00AM
Dec 22, 2025 02:30AM Daiichi Sankyo starts phase 3 trial for ENHERTU in endometrial cancer
Dec 22, 2025 02:30AM
Dec 22, 2025 02:30AM
Dec 15, 2025 02:30PM
Dec 15, 2025 02:30PM
Dec 15, 2025 09:00AM
Dec 9, 2025 07:01AM
Dec 9, 2025 07:00AM DESTINY-Ovarian01 Phase 3 Trial of ENHERTU® Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Oct 30, 2025 09:00PM
Oct 30, 2025 09:00PM
Oct 19, 2025 08:45AM
Oct 19, 2025 08:45AM
Oct 19, 2025 02:30AM
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM ENHERTU cuts breast cancer recurrence risk by 53% in post-surgery trial
Oct 18, 2025 10:30AM
Oct 18, 2025 10:30AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 6, 2025 02:30AM
Oct 1, 2025 07:00AM
Oct 1, 2025 07:00AM ENHERTU® Followed by THP Supplemental Biologics License Application Accepted in the U.S. for Patients with High-Risk HER2 Positive Early-Stage Breast Cancer Prior to Surgery
Sep 29, 2025 02:30AM
Sep 29, 2025 02:30AM
Sep 24, 2025 02:30AM
Sep 15, 2025 07:00AM
Sep 7, 2025 10:45AM
Sep 7, 2025 10:45AM
Aug 18, 2025 07:00AM Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
Jul 17, 2025 08:00AM
Jul 9, 2025 08:00AM
Jun 23, 2025 05:05PM
Jun 18, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 2, 2025 08:06AM
Jun 2, 2025 08:00AM ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 Phase 3 T
Jun 1, 2025 09:00AM

322,943 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All